



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/014,220	11/09/2001		Che-Kun James Shen	514162000120	5165
20872	7590	06/24/2004		EXAMINER	
MORRISON & FOERSTER LLP 425 MARKET STREET				KAUSHAL, SUMESH	
SAN FRANCISCO, CA 94105-2482				ART UNIT	PAPER NUMBER
-				1636	
			DATE MAILED: 06/24/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

× 1
1
1
٠.
$o_{j}$

## **Advisory Action**

Application No.	Applicant(s)	Applicant(s)		
10/014,220	SHEN, CHE-KUN JAMES	SHEN, CHE-KUN JAMES		
Examiner	Art Unit			
Sumesh Kaushal Ph.D.	1636			

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 10 May 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

Examination (RCE) in compliance with 37 CFR 1.114.	
PERIOD FOR REPLY [check either a) or b)]	
<ul> <li>a)</li></ul>	sion
fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).	or
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.	
2. The proposed amendment(s) will not be entered because:	
(a) 🗵 they raise new issues that would require further consideration and/or search (see NOTE below);	
(b) ☐ they raise the issue of new matter (see Note below);	
(c) ☐ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or	e
(d) they present additional claims without canceling a corresponding number of finally rejected claims.	
NOTE: <u>See Continuation Sheet</u> .	
3. Applicant's reply has overcome the following rejection(s): See Continuation Sheet.	
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendmen canceling the non-allowable claim(s).	it
5. ☑ The a) ☐ affidavit, b) ☐ exhibit, or c) ☑ request for reconsideration has been considered but does NOT place the application in condition for allowance because: <u>See Continuation Sheet</u> .	
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.	
7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.	•
The status of the claim(s) is (or will be) as follows:	
Claim(s) allowed:	
Claim(s) objected to:	
Claim(s) rejected: <u>21-34</u> .	
Claim(s) withdrawn from consideration:	
8. The drawing correction filed on is a) approved or b) disapproved by the Examiner.	
9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s)	
10. ☐ Other:  JEFFREY FREDMAN PRIMARY EXAMINER	
/\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	

P

Continuation of 2. NOTE: The recent amendment to claim 21 which recites "a chromosomally integrated transgene" and deleted of claim limitation "wherein said cell is from an animal" would require additional search and/or consideration under 35 USC 102/103 regarding prio art and double patenting issues. After the recent amendment the scope of instant invention as claimed is not limited to a cell obtained from a transgenic animal.

Continuation of 3. Applicant's reply has overcome the following rejection(s): Claims 21 regarding new matter rejection.

Continuation of 5. does NOT place the application in condition for allowance because: The recent amendment of claim 21 changes the scope of invention from a cell derived from a transgenic animal to an isolated cells which has been transformed in-vitro. This would requir additional search and/or consideration under 35 USC 102/103 regarding prior art and double patenting issues in view of U.S. Pat. No. 6,303845.